Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

Abstract The majority of lung cancer patients progressing from conventional therapies are refractory to PD‐L1/PD‐1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients with functional systemic CD4 T cells included all objec...

Full description

Saved in:
Bibliographic Details
Main Authors: Miren Zuazo, Hugo Arasanz, Gonzalo Fernández‐Hinojal, Maria Jesus García‐Granda, María Gato, Ana Bocanegra, Maite Martínez, Berta Hernández, Lucía Teijeira, Idoia Morilla, Maria Jose Lecumberri, Angela Fernández de Lascoiti, Ruth Vera, Grazyna Kochan, David Escors
Format: Article
Language:English
Published: Springer Nature 2019-06-01
Series:EMBO Molecular Medicine
Subjects:
B7‐H1
biomarker
immunotherapy
lung cancer
PD‐1/PD‐L1
Online Access:https://doi.org/10.15252/emmm.201910293
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.15252/emmm.201910293

Similar Items